Newsroom

Sorted by: Latest
-

Curatis et Neupharma annoncent la signature d’un accord de licence exclusive pour le développement et la commercialisation au Japon du corticoréline (C-PTBE-01) dans le traitement de l’œdème cérébral péritumoral

LIESTAL, Suisse et TOKYO--(BUSINESS WIRE)--Curatis Holding AG (SIX : CURN) et Neupharma Co., Ltd. (« Neupharma »), une société pharmaceutique japonaise spécialisée dans les troubles oncologiques, immunologiques, pulmonaires et cardiaques, annoncent aujourd’hui la signature d’un accord exclusif de licence et de développement pour la corticoréline (C-PTBE-01) au Japon. Selon les termes de l’accord, Neupharma obtiendra les droits exclusifs pour développer et commercialiser la corticoréline pour le...
-

BRIDGE Housing Exceeds $92 Million at First Close of New Impact Fund to Acquire and Create Affordable and Workforce Housing on the West Coast

SAN FRANCISCO--(BUSINESS WIRE)--BRIDGE Housing, the leading nonprofit affordable housing owner and developer on the West Coast, today announced the first close of BRIDGE Housing Impact Fund I with more than $92 million, marking a major milestone for the innovative investment platform to accelerate the acquisition, preservation, and construction of affordable and workforce housing in high-cost markets. The initial close brings together a distinguished group of institutional and mission-aligned i...
-

Curatis und Neupharma geben exklusive Lizenzvereinbarung zur Entwicklung und Vermarktung von Corticorelin (C-PTBE-01) zur Behandlung von peritumoralem Hirnödem in Japan bekannt

LIESTAL, Schweiz & TOKIO--(BUSINESS WIRE)--Die Curatis Holding AG (SIX: CURN) und Neupharma Co., Ltd. („Neupharma“), ein japanisches Pharmaunternehmen, das sich auf Onkologie, Immunologie, Pulmologie und Kardiologie spezialisiert hat, geben heute eine exklusive Lizenz- und Entwicklungsvereinbarung für Corticorelin (C-PTBE-01) in Japan bekannt. Gemäß den Vertragsbedingungen erhält Neupharma die exklusiven Rechte zur Entwicklung und Vermarktung von Corticorelin zur Behandlung von peritumoralem Hi...
-

HyperLight, UMC, and Wavetek Announce Strategic Partnership for High-Volume Foundry Production of TFLN Chiplet™ Platform

CAMBRIDGE, Mass. & HSINCHU, Taiwan--(BUSINESS WIRE)--HyperLight Corporation (“HyperLight”), United Microelectronics Corporation (NYSE: UMC; TWSE: 2303)(“UMC”), and Wavetek Microelectronics Corporation (“Wavetek”), a wholly owned subsidiary of UMC, today announced a strategic manufacturing partnership for high-volume foundry production of HyperLight’s TFLN (thin-film lithium niobate) Chiplet™ Platform on both 6-inch and 8-inch wafers. The collaboration marks a major inflection point in the comme...
-

Riassunto: ATLAS Infrastructure investe in H2O America e supporta la strategia di crescita a lungo termine

SYDNEY e LONDRA--(BUSINESS WIRE)--ATLAS Infrastructure (“ATLAS”) è un investitore specializzato in infrastrutture quotate in borsa che gestisce fondi per conto di clienti di infrastrutture a lungo termine. A seguito del recente posizionamento di capitale, gli account attivamente gestiti di ATLAS detengono circa il 10,8% dei diritti di voto e degli interessi economici in H2O America (“H2O”). ATLAS è stata lieta di supportare la strategia a lungo termine di H2O per investire nelle attività dei se...
-

Resumen: Curatis y Neupharma anuncian un acuerdo de licencia exclusiva para desarrollar y comercializar en Japón la corticorelina (C-PTBE-01) para el tratamiento del edema cerebral peritumoral

LIESTAL, Suiza y TOKIO--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) y Neupharma Co., Ltd. («Neupharma»), empresa farmacéutica japonesa especializada en oncología, inmunología, neumología y cardiología, acaban de anunciar un acuerdo exclusivo de licencia y desarrollo para la corticorelina (C-PTBE-01) en Japón. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original,...
-

Orbia Releases 2025 Impact Report; Demonstrating Sustainability-Enabled Resilience & Disciplined Value Creation

BOSTON--(BUSINESS WIRE)--Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) (“Orbia” or “the Company”) today released its 17th annual report, detailing its 2025 performance and strategic initiatives driving resilience and long-term value. “Over more than 70 years, Orbia has evolved into a global, purpose-driven company built to perform across decades,” said Sameer Bharadwaj, Chief Executive Officer of Orbia. “In 2025, we made deliberate choices to sharpen our portfolio, reinforce financial...
-

Travel + Leisure Co. Named to Newsweek’s Inaugural “America’s Most Charitable Companies” List

ORLANDO, Fla.--(BUSINESS WIRE)--Leading leisure travel company Travel + Leisure Co. today announced it was named by Newsweek as one of America’s Most Charitable Companies in 2026....
-

Riassunto: Curatis e Neupharma annunciano un accordo di licenza esclusiva per sviluppare e commercializzare corticorelin (C-PTBE-01) per il trattamento dell'edema cerebrale peritumorale in Giappone

LIESTAL, Svizzera e TOKYO--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) e Neupharma Co., Ltd. (“Neupharma”), azienda farmaceutica giapponese specializzata in malattie oncologiche, autoimmuni, polmonari e cardiache, oggi annuncia la firma di un accordo esclusivo di licenza e sviluppo per corticorelin (C-PTBE-01) in Giappone. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del le...
-

Axiamatic Launches With $54M from Greylock and Bessemer to End the Era of Failed Enterprise Transformations

SAN FRANCISCO--(BUSINESS WIRE)--Axiamatic, the agentic platform to accelerate enterprise transformations, today emerged from stealth with $54 million in funding from Greylock Partners and Bessemer Venture Partners. Axiamatic’s platform is purpose-built to supercharge how every team sees, understands, decides, and acts at every step during an enterprise transformation. The company is already helping Fortune 500 companies, large enterprises, and system integration partners run successful transfor...